Tempus AI Reports Q3 2026 Growth Driven by Oncology Volume and Data Licensing
Tempus AI (TEM) reported strong third-quarter results for 2026, with total revenue reaching $411.5 million, a 23% increase year-over-year. The growth was primarily fueled by a 32% surge in oncology volume and a 33% rise in Data and Applications revenue. Notably, the company's MRD (Minimal Residual Disease) testing saw a massive 300% increase compared to the previous year. The company achieved positive Adjusted EBITDA of $25.6 million, a significant improvement from $1.5 million in the same period last year. While reporting a net loss of $14.9 million due to stock-based compensation and unrealized gains, Tempus maintained a strong liquidity position with $854.4 million in cash and marketable securities. Management provided full-year revenue guidance of approximately $1.60 billion.
Topics: adjusted EBITDA data licensing oncology sequencing revenue growth
Read the full article at Motley Fool
Part of the story Chemours Reports Q3 2026 Growth Driven by Titanium Technologies and AI Infrastructure Demand (16 articles)